Treatment Of Allergic Diseases Research Articles

Biological Effects and Clinical Application of the Anti-Immunoglobulin E Antibody

Immunoglobulin E (IgE) plays a crucial role in the occurrence and development of allergic diseases. Since the discovery of IgE in 1967, the pathogenesis of allergic inflammatory diseases has been progressively revealed thereby providing a theoretical foundation for the development of therapeutic anti-IgE antibodies, which have emerged as a new method for the treatment of allergic diseases. In this paper, we aim to summarize and elaborate on the mechanism of biological effects and clinical application of anti-IgE antibodies by examining related global literature, particularly regarding Omalizumab in the past 5 years. We seek to establish theoretical foundations for the formation of new strategies for anti-allergic treatment.

Jingfang Granules alleviates OVA-induced allergic rhinitis through regulating endoplasmic reticulum stress signaling pathway

Ethnopharmacological relevanceJingfang Granules (JF) is a modified herbal compound preparation that is empirically used in clinical practice for the treatment of allergic diseases. Nevertheless, the role of JF in allergic rhinitis (AR) has yet to be demonstrated, and its potential mechanisms of action remain to be fully evaluated. Aim of studyThe objective of this research is to examine the underlying mechanisms by which JF can be used to treat AR. This will be achieved through the use of an ovalbumin (OVA) /aluminum hydroxide AR model in mice. Materials and methodsICR mice were administered an intraperitoneal (i.p.) injection of OVA/aluminium hydroxide in order to permit the establishment of an AR model. Following the intragastric administration of JF to the mice, testing nose scratching and sneezing behavior in mice to determine modeling status, and stained transverse sections of the mouse nose using the Hematoxylin and Eosin (H&E) method were in vitro evaluated to assess the histological effects of JF on mice with AR. The regulatory network was subjected to proteomic and metabolomic investigation. The expression of serum cytokines as well as histamine (HIS) was detected using ELISA kits. Protein expression in nasal mucosal tissues was identified through the use of a Western blot. ResultsJF demonstrated a notable reduction in nose-scratching and sneezing in AR mice. Concurrently, JF markedly reduced IgE, IL-4, IL-6, IL-13, TNF-α and HIS levels while elevating IFN-γ levels in the serum of AR mice. This was achieved by inhibiting the endoplasmic reticulum (ER) stress-related protein associated proteins including GADD and ATF4, p-eIF2α, p-IRE1α, XBP1s and p-PERK. Proteomics, metabolomics, Western blotting and Quantitative Real-time polymerase chain reaction (qPCR) results confirmed that JF inhibits the glycolysis/arginine biosynthesis pathway by suppressing the ER stress (ERs) signaling pathway, which in turn inhibits the inflammatory response. ConclusionFindings from the present study indicate that JF is an efficacious treatment for OVA/aluminum hydroxide-induced nasal mucosal injury and inflammation in mice. Furthermore, the study demonstrated that JF exhibited anti-AR clinic pharmacological effects by modulating the ERs signaling pathway and inhibiting glycolysis as well as arginine biosynthesis.

Intralymphatic Immunotherapy with Ultrasound Guidance Seems to Be Associated with Improved Clinical Effect in Canine Atopic Dermatitis-A Retrospective Study of 109 Cases.

Background: Intralymphatic immunotherapy (ILIT) has been used successfully in both human and veterinary medicine as a safe and effective treatment for allergic diseases. Initially, ILIT was administered by ultrasound guidance, but palpation-based injections have become more popular among veterinary dermatologists. Data from human medicine, however, show that precise injection into the lymph node is mandatory, and injection quality clearly correlates with clinical response. Hypothesis: Our aim was to assess the impact of the injection method (ultrasound guidance versus palpation-based guidance) on clinical response in dogs with atopic dermatitis. Methods: A total of 129 canine atopic dermatitis (CAD) cases treated with ILIT between 2014 and 2022 were retrieved from the hospital clinical database. The included dogs had to receive at least three intralymphatic injections administered either by palpation or ultrasound guidance. Those cases were retrospectively assessed and compared regarding clinical response to ILIT. Results: In total, 84 dogs received ILIT by ultrasound guidance, and in 25 dogs, ILIT was injected based on palpation. The success rate of ILIT was significantly higher in the ultrasound guidance group when compared to palpation-based injections. Conclusions: Low-quality injections must be considered as a possible reason for ILIT failure in dogs. Further prospective and controlled studies are necessary to confirm these results.

Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.

Allergen immunotherapy is a disease-modifying treatment for allergic diseases. The predominant traditional immunotherapy is through subcutaneous administration of allergens to gradually desensitize allergic individuals. While effective, traditional allergen immunotherapy approaches are often lengthy, time consuming for patients and can result in local or systemic adverse reactions. Nontraditional immunotherapies are emerging as promising alternatives, offering potentially more convenient, safe and efficacious treatment options. This review sought to comprehensively examine the safety, efficacy and performance of various nontraditional immunotherapies for environmental allergens. Nontraditional immunotherapy approaches covered in this review include sublingual, local nasal, intralymphatic rush and ultra-rush immunotherapy, allergoid, microbial and anti-IgE immunotherapies. Nontraditional immunotherapies show significant promise in addressing the limitations of traditional subcutaneous immunotherapy. Methods like intralymphatic and rush immunotherapy offer shorter treatment regimens, enhancing patient adherence and convenience. The co-administration of probiotics or monoclonal antibodies, like omalizumab, with AIT appears to improve treatment efficacy and safety. Despite these advancements, further large-scale, long-term studies are needed to establish standardized protocols, dosing and validate long-term effects of these nontraditional immunotherapies. Standardizing outcome measurements across studies is crucial for accurate comparisons of nontraditional immunotherapies prior to widespread clinical adoption of these innovative techniques.

B-060 Prevalence of CCD and profilins antibodies in a seasonal allergy study

Abstract Background Allergen sources are complex and heterogeneous mixtures of proteins, which may contain from innocuous IgE-binding structures such as CCDs (cross-reactive carbohydrate determinants), which are not associated with symptoms, to a panallergen such as profilin, which is associated with multiple sensitizations to pollen and pollen-food-latex syndromes. CCDs are present in many plant and animal allergens and cause strong cross-reactivity due to the high similarity of their structure. They complicate the interpretation of positive in vitro diagnostic results because they do not associate symptomatology and, thats why, the determination of specific IgE antibodies against CCDs can provide useful information when positive IgE results are not consistent with the clinical picture. Profilins are ubiquitous proteins present in all eukaryotic cells and identified as allergens in pollen, latex and plant foods. The highly conserved structure explains the cross-reactivity of IgE antibodies against plant profilins and their designation as panallergens. As a panallergen, profilin is associated with multiple pollen sensitization and pollen-food-latex syndromes that the allergist must be aware of for accurate diagnosis and successful treatment of allergic diseases. We intend to evaluate the prevalence of these two markers with a new diagnostic tool, since profilins and CCDs are the substances most likely to cause in vitro cross-reactivity. Methods In our study 8,242 adults who presented rhinoconjunctivitis and visited their primary care center were included. The samples were analyzed in serum samples which were routinely processed in our laboratory with the EUROLINE Mediterranean Inhalation 2 (IgE) assay from Euroimmun® from February to July 2023, according to the manufacturer’s protocols. Patients with specific IgE levels ≥ 0.35 kU/L were identified as sensitized to allergen. Results A total of 8,242 patients were enrolled in this study, 5,173 women and 3,069 men, ranging in age from 15 to 65 years. Of these, 279 patients (3.39%) had antibodies against CCD, 570 (6.92%) antibodies against profilins and 183 (2.22%) had both. A higher prevalence of these antibodies was observed in men (CCD, n = 168, 5.47%; Profilins, n = 308, 10.04%) than in women (CCD, n = 111, 2.15%; Profilins, n = 262, 5.06%). Both markers were more frequently found in the presence of specific IgE antibodies to grass and weed pollens. Conclusions The possibility of detecting the presence of IgE antibodies against CCD and panallergenic profilins is useful to detect cross-reactivity in vitro, which could explain the differences found between laboratory results and patients' symptoms, helping the allergist to make a diagnosis with greater certainty and accuracy.

Quercetin Attenuates MRGPRX2-Mediated Mast Cell Degranulation via the MyD88/IKK/NF-κB and PI3K/AKT/ Rac1/Cdc42 Pathway.

CMRF35-like molecule-1 (CLM-1) is a receptor of the CD300 family that inhibits MRGPRX2-mediated mast cell degranulation. Understanding the role and mechanism of CLM-1 agonist has significant implications for the treatment of allergic disease. Quercetin is a natural small molecule compound derived from plants and vegetables that has been shown to prevent histamine release by immune cells. This study aims to examine the inhibitory effects of quercetin on MRGPRX2-mediated mast cell degranulation via CLM-1. We found that C48/80 stimulation resulted in significantly increased release of β-hexosaminidase, histamine and Ca2+ in CLM-1-knockdown LAD2 cells than in NC-LAD2 cells. Surface plasmon resonance (SPR) and molecular docking analyses revealed high-affinity binding between quercetin and CLM-1 (K D = 2.962×10-5 mol/L) mediated by the formation of hydrogen bonds. In addition, quercetin can selectively bind to CLM-1 on mast cells, leading to SHP-1 phosphorylation and subsequent inhibition of downstream MyD88/IKK/NF-κB signaling. Furthermore, activation of CLM-1 modulated the surface expression of MRGPRX2 by inhibiting F-actin, leading to internalization of the MRGPRX2 receptor via the PI3K/AKT/ Rac1/Cdc42 pathway. Quercetin is a promising treatment for allergic diseases by acting as a CLM-1 agonist that inhibits MRGPRX2-mediated mast cell degranulation.

High-risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database.

Cetirizine and Loratadine are the two best-selling second-generation antihistamines for allergic diseases. This study aims to provide a comparative analysis of the differences in adverse drug events (ADEs) between these two medications, which can assist clinicians in making appropriate treatment decisions. ADE reports related to Cetirizine and Loratadine obtained from the FDA adverse event reporting system (FAERS) database were analyzed using disproportionality analysis and Bayesian analysis to evaluate and compare the ADE signals of both drugs. A total of 28,051 and 28,073 ADE reports were retrieved from the FAERS database related to Cetirizine and Loratadine, respectively, with both drugs showing a predominance of middle-aged females. Specifically, Loratadine was associated with respiratory symptoms, mainly nasal symptoms such as rhinorrhea (n=326, ROR 6.75), sneezing (n=251, ROR 15.24), and nasal congestion (n=185, ROR 4.25), while Cetirizine did not show this association. Notably, both drugs exhibited strong signals for somnolence in the nervous and psychiatric systems, especially Cetirizine (Cetirizine, n=2556, ROR 10.52 vs. Loratadine, n=1200, ROR 7.76). Additionally, Cetirizine itself showed strong signals for attention disturbance (n=233, ROR 3.3), while Loratadine was associated with nervousness (n=145, ROR 3.3). Further exploration revealed more severe adverse reactions closely associated with Cetirizine, including hallucinations, aggression, and abnormal behavior. Importantly, Cetirizine was significantly associated with the occurrence of pericarditis (n=138, ROR 8.13), potentially leading to serious adverse consequences. Compared to Loratadine, Cetirizine poses a greater potential risk in the nervous and psychiatric systems. Additionally, this study reveals previously underestimated potential cardiac toxicity of Cetirizine; albeit at a relatively low incidence rate, the high signal intensity warrants further attention and exploration. These findings highlight the need for enhanced patient monitoring and therapy optimization when prescribing these medications, ensuring better management of allergic diseases while minimizing risks.

Regional features of sensitization to various allergens in children with allergic diseases, taking into account the formed exposome.

Background. According to statistical data from the WHO and a number of researchers, up to 40% of the world's population. Assessing the impact of the exposome in the population of the Russian Federation is a crucial issue of national public health care, the solution of which will provide a personalised approach to the treatment and prevention of allergic diseases in the local population. The aim of this study was to evaluate the sensitisation profile in children with allergic diseases from different regions of Russia. Methods. The study included sick children with allergic manifestations from different regions of the Russian Federation. A separate group consisted of children from the Far North regions from 2 to 12 years of age. The concentration of total IgE and allergen-specific immunoglobulins in blood was determined retrospectively on the basis of analyses of results obtained in CDCs performing immunoblotting tests using the Allergy-Q test system. Results. It was found that in more than 60% of cases allergic reactions are represented by combined manifestations. Allergic rhinitis took the second place, up to 65.32% of cases. Atopic dermatitis in the structure of allergic diseases took the third place, which was about 22,06%. The diagnosis of allergic conjunctivitis in our study was established in 15.38% of cases. Less than 5% in the structure of allergies was occupied by urticaria. In the group of household allergens the first place is occupied by cat, then dog and already then house dust. Among respiratory allergens, birch and/or other trees, weeds and mugwort are the leaders. Food sensitisation in children is mainly to milk, egg, fish and seafood. Conclusion. The peculiarities of sensitisation revealed in different regions are easily explained by the formed exposomes. The obtained data can be used to develop measures of prevention, diagnosis and treatment of allergic diseases.

Otolaryngic Allergy Patient Journey Mapping: A Framework for Allergy Immunotherapy Adherence.

Allergen-specific immunotherapy (AIT) is an effective treatment for allergic disease but requires long treatment duration and premature cessation is of significant concern. Drivers of premature cessation remain poorly understood and no predictive models currently exist. We hypothesized that a novel patient journey map and de novo real-time patient electronic health status instruments (eHSIs) could effectively capture patient perceived cost, commitment, and treatment benefit to identify individual patients at risk for premature AIT cessation. Cross-Sectional Observational Study. A single Otolaryngology allergy immunotherapy (AIT) program was studied over 5 years. Instances of premature cessation were classified. An Otolaryngic Allergy Patient Journey Map was developed to identify and target automated, real-time, patient-reported, electronic health status instrument responses. Data capture was robust, with 61,406 data points collected and an eHSI survey completion rate of 81.3%. However, based on correlation analysis and logistic regression alone, real-time eHSI responses were not predictive of individual patient premature AIT cessation. A total of 597 AIT patients discontinued treatment prematurely: 64.4% stopping within the first year. Specifically, 74.0%-76.3% of subcutaneous AIT patients and 88.5%-100% of sublingual AIT patients did not complete the minimum recommended treatment duration of 3 years. Patient journey mapping can aid in the design of longitudinal care models and patient engagement strategies. Yet, eHSI patient responses of perception of AIT cost, benefit, and convenience did not correlate with the likelihood of premature treatment cessation. Our imperfect clinical intuition may not account for the dynamic drivers of premature AIT discontinuation. Future development of predictive tools feed by large patient-centric data sets may be incorporated into routine practice resulting in delivery of a more streamlined and personalized approach with reduced premature AIT cessation, improved outcomes, and reduced health care expenditures. NA Laryngoscope, 2024.

Antipruritic effect of ursolic acid through MRGPRX2/MrgprB2-dependent inhibition of mast cell degranulation and reduced TSLP production

Ursolic acid (UA), a pentacyclic triterpene, exhibits diverse pharmacological effects, including potential treatment for allergic diseases. It downregulates thymic stromal lymphopoietin (TSLP) and disrupts mast cell signaling pathways. However, the exact molecular mechanism by which UA interferes with mast cell action remains unclear. Therefore, the current study aimed to uncover molecular entities underlying the effect of UA on mast cells and its potential antipruritic effect, specifically investigating its modulation of key molecules such as TRPV4, PAR2, and MRGPRX2, which are involved in TSLP regulation and sensation.Calcium imaging experiments revealed that UA pretreatment significantly suppressed MRGPRX2 activation (and its mouse orthologue MrgprB2), a G protein-coupled receptor predominantly expressed in mast cells. Molecular docking predictions suggested potential interactions between UA and MRGPRX2/MrgprB2. UA pretreatment also reduced mast cell degranulation through MRGPRX2 and MrgprB2-dependent mechanisms. In a dry skin mouse model, UA administration decreased tryptase and TSLP production in the skin, and diminished TSLP response in the sensory neurons. While PAR2 and TRPV4 activation enhances TSLP production, UA did not inhibit their activity. Notably, UA attenuated compound 48/80-induced scratching behaviors in mice and suppressed spontaneous scratching in a dry skin model.The present study confirms the effective inhibition of UA on MRGPRX2/MrgprB2, leading to reduced mast cell degranulation and suppressed scratching behaviors. These findings highlight the potential of UA as an antipruritic agent for managing various allergy- or itch-related conditions.

Is there a role for probiotics in prevention and treatment of allergic diseases in children? – review of literature

Is there a role for probiotics in prevention and treatment of allergic diseases in children? – review of literature

Analysis of the prevalence and experience of treatment of allergic diseases of the respiratory tract in Mongolia

Analysis of the prevalence and experience of treatment of allergic diseases of the respiratory tract in Mongolia

Allergen Microarrays and New Physical Approaches to More Sensitive and Specific Detection of Allergen-Specific Antibodies.

The prevalence of allergic diseases has increased tremendously in recent decades, which can be attributed to growing exposure to environmental triggers, changes in dietary habits, comorbidity, and the increased use of medications. In this context, the multiplexed diagnosis of sensitization to various allergens and the monitoring of the effectiveness of treatments for allergic diseases become particularly urgent issues. The detection of allergen-specific antibodies, in particular, sIgE and sIgG, is a modern alternative to skin tests due to the safety and efficiency of this method. The use of allergen microarrays to detect tens to hundreds of allergen-specific antibodies in less than 0.1 mL of blood serum enables the transition to a deeply personalized approach in the diagnosis of these diseases while reducing the invasiveness and increasing the informativeness of analysis. This review discusses the technological approaches underlying the development of allergen microarrays and other protein microarrays, including the methods of selection of the microarray substrates and matrices for protein molecule immobilization, the obtainment of allergens, and the use of different types of optical labels for increasing the sensitivity and specificity of the detection of allergen-specific antibodies.

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.

Interleukin-5 functions as a B-cell differentiation factor, but more importantly, in the context of this review, it plays a variety of roles in eosinophil biology, including eosinophil differentiation and maturation in the bone marrow, and facilitates eosinophil migration to tissue sites, usually in the context of an allergic reaction. Given the availability of selective anti-IL-5 drugs such as mepolizumab and reslizumab, as well as the IL-5 receptor antagonist benralizumab, it is worth investigating whether they could be used in some cases of allergic disease. Asthma has a well-documented involvement of IL-5 in its pathophysiology and has clear benefits in the case of anti-IL-5 therapy; therefore, current knowledge is presented to provide a reference point for the study of less-described diseases such as atopic dermatitis, chronic rhinosinusitis, chronic spontaneous urticaria, and its association with both IL-5 and anti-IL-5 treatment options. We then review the current literature on these diseases, explain where appropriate potential reasons why anti-IL-5 treatments are ineffective, and then point out possible future directions for further research.

БЕЗОПАСНОСТЬ ПРИМЕНЕНИЯ ОМАЛИЗУМАБА У РАЗЛИЧНЫХ ГРУПП ПАЦИЕНТОВ

The article is devoted to an analytical review of studies to assess the clinical safety of omalizumab. The analysis showed that targeted therapy using genetically engineered biological drugs, which include, in particular, omalizumab, is increasingly used in the treatment of allergic diseases. In general, most studies show the clinical efficacy of omalisamab in bronchial asthma, allergic rhinitis, anaphylactic conditions, allergic urticaria, both in adults and children. However, there are isolated reports that allow us to talk about individual restrictions in the use of this drug associated with adverse reactions. Anaphylactic reactions have been most commonly reported during the administration of omalizumab. There are reports that indicate itching and rashes on the skin as undesirable reactions. In children, dyspeptic disorders are a common complaint. Reliable data on the initiation of malignancy processes against the background of the use of omalizumab have not been established. Quite rarely, as adverse reactions, the authors note eosinophilic granulomatosis with polyangiitis and thromboembolic complications. The authors draw attention to the need for a thorough collection of allergic anamnesis in patients, a clear selection of the dose of the drug, and monitoring patients in the first hours after the administration of the drug. The analysis data are the theoretical basis for improving the system for ensuring the safety of medicines and notifying supervisory authorities of adverse reactions to the use of medicines.

Is It Possible to Predict Systemic Adverse Effects in Subcutaneous Allergen Immunotherapy? Single-Center Experience

Introduction: Subcutaneous immunotherapy (SCIT) is the oldest and an efficient immunotherapy method that has been used for the treatment of allergic diseases. Systemic adverse effects (SAEs) may occur during the SCIT. For this reason, there may be problems in the continuing treatment. In this study, we primarily aimed to determine the frequency of SAEs, the risk factors that may be associated with SAEs, and clinical and laboratory parameters that can predict systemic reactions in the patients who underwent SCIT. Second, we aimed to evaluate the reasons for discontinuing SCIT and the conditions special to Turkey. Methods: The files of 295 patients who had received SCIT were evaluated retrospectively. Results: SCIT was administered against house dust mites (HDM) in almost all patients (n: 291, 98.6%). A total of 14,357 injections were administered to 295 patients included in the study, and 47.8% (n: 141) of the patients discontinued treatment. The most common reason for discontinuing treatment was the supply problem in Turkey for immunotherapy preparations (n: 70, 49.6%). The second reason was that the injection visits were not continued regularly, even though there were no adverse effects related to the treatment (n: 44, 31.2%). SAEs were observed in 16.6% of the patients and 0.66% of the injections. SAEs were more frequent in girls, in asthmatic patients, and in moderate asthmatic patients (p = 0.005, p = 0.016, p = 0.043, respectively). Treatment was terminated in 13 patients (4.4%) due to SAEs. The most common SAE was bronchoconstriction (n: 40, 85.1%). None of our patients developed hypotension or loss of consciousness. Median blood eosinophil count and basophil count and the skin prick test diameter for Dermatophagoides farinae were observed to be significantly higher in the group with SAE (p = 0.024, p = 0.034, p = 0.045, respectively). Conclusion: Although SAE may develop in pediatric patients undergoing HDM-specific SCIT, severe reactions are rare. Girls, asthmatic patients, especially moderate asthmatic patients, and patients with high blood eosinophil and basophil levels should be monitored more carefully for the development of SAE.

Biodegradable Mesoporous Organosilica-Based Nanostabilizer Targeting Mast Cells for Long-Term Treatment of Allergic Diseases.

Allergic diseases are immune system dysfunctions mediated by mast cell (MC) activation stimulated by specific allergens. However, current small molecular MC stabilizers for allergic disease prevention often require multiple doses over a long period of time and are associated with serious side effects. Herein, we develop a diselenide-bridged mesoporous silica nanostabilizer, proving that it could specifically target sensitized MCs via the recognition of IgE aptamer and IgE. Meantime, the IgE aptamer can also mitigate allergic reactions by preventing re-exposure of allergens from the surface of sensitized MCs. Furthermore, the diselenide-bridged scaffold can be reduced by the intracellular excessive ROS, subsequently achieving redox homeostasis via ROS depletion. Finally, the precise release of small molecular MC stabilizers along with the biodegradation of nanocarrier can stabilize the membranes of MCs. In vivo assays in passive cutaneous anaphylactic (PCA) and allergic rhinitis (AR) mice indicated that our current strategy further endowed it with a high efficacy, long-term therapeutic time window, as well as negligible inflammatory side effects for allergic diseases, offering a promising therapeutic strategy for the clinical generalization of allergic diseases.

Cellular metabolism and hypoxia interfacing with allergic diseases.

Allergic diseases display significant heterogeneity in their pathogenesis. Understanding the influencing factors, pathogenesis, and advancing new treatments for allergic diseases is becoming more and more vital as currently, prevalence continues to rise, and mechanisms of allergic diseases are not fully understood. The upregulation of the hypoxia response is linked to an elevated infiltration of activated inflammatory cells, accompanied by elevated metabolic requirements. An enhanced hypoxia response may potentially contribute to inflammation, remodeling, and the onset of allergic diseases. It has become increasingly clear that the process underlying immune and stromal cell activation during allergic sensitization requires well-tuned and dynamic changes in cellular metabolism. The purpose of this review is to examine current perspectives regarding metabolic dysfunction in allergic diseases. In the past decade, new technological platforms such as "omic" techniques have been applied, allowing for the identification of different biomarkers in multiple models ranging from altered lipid species content, increased nutrient transporters, and altered serum amino acids in various allergic diseases. Better understanding, recognition, and integration of these alterations would increase our knowledge of pathogenesis and potentially actuate a novel repertoire of targeted treatment approaches that regulate immune metabolic pathways.

Modulation of the Immune System Mechanisms using Probiotic Bacteria in Allergic Diseases: Focus on Allergic Retinitis and Food Allergies.

Allergic illnesses occur when an organism's immune system is excessively responsive to certain antigens, such as those that are presented in the environment. Some people suffer from a wide range of immune system-related illnesses including allergic rhinitis, asthma, food allergies, hay fever, and even anaphylaxis. Immunotherapy and medications are frequently used to treat allergic disorders. The use of probiotics in bacteriotherapy has lately gained interest. Probiotics are essential to human health by modulating the gut microbiota in some ways. Due to probiotics' immunomodulatory properties present in the gut microbiota of all animals, including humans, these bacterial strains can prevent a wide variety of allergic disorders. Probiotic treatment helps allergy patients by decreasing inflammatory cytokines and enhancing intestinal permeability, which is important in the battle against allergy. By altering the balance of Th1 and Th2 immune responses in the intestinal mucosa, probiotics can heal allergic disorders. Numerous studies have shown a correlation between probiotics and a reduced risk of allergy disorders. A wide range of allergic disorders, including atopic dermatitis, asthma, allergic retinitis and food allergies has been proven to benefit from probiotic bacteria. Therefore, the use of probiotics in the treatment of allergic diseases offers a promising perspective. Considering that probiotic intervention in the treatment of diseases is a relatively new field of study, more studies in this regard seem necessary.

Initial study of trap and identification of environmental pollens and fungi spores in Samborondon, Ecuador

Initial study of trap and identification of environmental pollens and fungi spores in Samborondon, Ecuador Introduction: The identification of local aeroallergens in any geographical area is essential for the specific diagnosis and treatment of allergic diseases. Our objective was to identify and registry the most important aeroallergens trapped at the aerobiology station in the city of Samborondon, Ecuador.Material and methods:Pollen grains and fungal spore counts were performed according to the standardized technique with a Hirst-type collection equipment, Burkard spore trap for seven days, following the recommendations of the National Allergy Bureau (NAB) of the American Academy of Allergy Asthma and Immunology (AAAAI). The equipment was installed on the roof of the Universidad de Especialidades Espiritu Santo (UEES), 25 m above ground level, coordinates: 2°07 ́57 ́ ́S 79°52 ́06 ́ ́W, in the city of Samborondon. The sampling period was performed from November 2022 to April 2023.Results:We identified the following pollen families: Poaceae (258 grains/m3), Apocynaceae (Plumeria rubra pc) 214 grains/m3, Lamiaceae (180 grains/m3), Asteraceae - Ambrosía spp.- (60 grains/m3), Chenopodiacea (27 grains/m3), Myrtaceae (17 grains/m3), Pinaceae (11 grains/m3), Betulaceae (7 grains/m3).Also identified fungical spores: Fuzariella spp./Leptosphaeria spp. (1899/m3), Cladosporium spp. (1407/m3), Nigrospora spp. (1183/m3), Dreschlera/Helmintosporum spp. (329/m3), Alternaria spp. (98/m3), Pithomyces spp. (79/m3), Curvularia spp. (48/m3), Stemphylium spp. (46/m3).Conclusions:We reported the first study of aerobiology (capture and identification of environmental pollens and fungi) in the city of Samborondon. The inhabitants of this area are exposed to different aeroallergens with a predominance of Poaceaes pollen and Fuzzariella spp./Leptosphaeria spp. spores. The identified allergens should be part of the usual allergy studies. The results of this first preliminary study should be compared with information from the forthcoming years, which will help to identify variations in the concentration of seasonal aeroallergens, annual fluctuations, and extend the traps to other parts of the city.Key words: aerobiology, allergic rhinitis, allergic conjunctivitis, pollens.